Evidence map›Paper›PMID 41145918›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

RECIP 1.0 more predictive of overall survival than PSMA PET progression criteria in biochemically recurrent prostate cancer.

Kaylee Molin, Jeremy S L Ong, Steven Van Der Werf, Roslyn J Francis, Ghulam Mubashar Hassan, Martin A Ebert, Jake Kendrick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kaylee MolinSchool of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia. kaylee.molin@research.uwa.edu.au.ORCID 0009-0006-8445-051X
Jeremy S L OngDepartment of Nuclear Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia.ORCID 0000-0001-5101-6107
Steven Van Der WerfDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Roslyn J FrancisDepartment of Nuclear Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.ORCID 0000-0002-6256-1351
Ghulam Mubashar HassanSchool of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia.ORCID 0000-0002-6636-8807
Martin A EbertSchool of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia.ORCID 0000-0002-6875-0719
Jake KendrickSchool of Physics, Mathematics and Computing, University of Western Australia, Crawley, WA, Australia.ORCID 0000-0001-6524-539X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeUp to 40% of prostate cancer (PCa) patients experience biochemical recurrence (BCR) after primary treatment, but reliable tools for risk stratification in this setting are limited. This study compared Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) and PSMA PET Progression (PPP) criteria in predicting overall survival (OS) and prostate-specific antigen progression-free survival (PSA-PFS). As a secondary aim, PROMISE-based nomograms were assessed as tools for OS prediction.

methodsA cohort of 154 BCR PCa patients with baseline and follow-up [

resultsRECIP-defined progressive disease (RECIP-PD) was most strongly associated with OS, identifying patients at highest risk of death (median OS 53.2 months; HR 4.62; 95% CI: 2.41-8.87; p < 0.001). PPP-based criteria were also prognostic for OS, and were the only framework associated with PSA-PFS. PROMISE-based nomograms were predictive of OS, with performance comparable to PPP criteria. By treatment type, RECIP-PD performed best in androgen deprivation therapy, PPP-Max SUV in radiotherapy, and PPP-Volume in combined ADT + radiotherapy. SUV-based PPP criteria were most predictive of PSA-PFS in combined ADT + radiotherapy.

conclusionIn BCR PCa, RECIP 1.0 best predicts OS, PPP criteria better predict PSA progression, and PROMISE nomograms provide a single-timepoint approach to OS risk stratification. TRIAL REGISTRATION NUMBER: ACTRN ACTRN12615000608561. Registered 11 June 2015. Retrospectively registered.

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overDisease ProgressionGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNomogramsRecurrencegallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesBiochemically recurrent prostate cancerPPPPSMA PETRECIP 1.0Response assessment frameworks

Identifiers

PMID41145918
PMCPMC12920775

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.